Abstract:Abstract High-grade serous ovarian cancer (HGSC) is the most common form of epithelial ovarian cancer, typically diagnosed at advanced stage with five-year survival of only 38%. Herein, we used 149 treatment-naïve and 65 after-treatment samples subjected to whole-genome sequencing from 55 HGSC patients to reconstruct evolutionary histories, characterize clonal compositions and intra- and inter-tumor heterogeneity, in order to identify mechanisms that drive treatment failure. Using clonal information from the phylogenetic trees we quantified intra- and intertumor heterogeneity and identified three types of clonal compositions corresponding to three evolutionary states (“adaptive”, “maintaining” and “evolving”) of treatment-naïve HGSC tumors. The branch depths from phylogenetic trees were used to quantify “clonal age” for each state. The “adaptive” state showed the highest clonal age, followed by the “maintaining” state, and the “evolving” being the youngest, least evolved tumor state. The three states have significantly different survival association, “evolving” the longest and “maintaining” the shortest (p = 0.029). Pathway analysis of genes harboring branch mutations revealed that the three states are characterized by unique signaling cascades, with MAPK, PI3K/AKT, and NOTCH signaling significantly enriched at “evolving”, “maintaining”, and “adaptive” states, respectively. Furthermore, we suggest two evolutionary trajectories originating from “evolving” state towards “maintaining” via PI3K/AKT activation and extensive cytokine signaling or towards “adaptive” state via RAS/RAF/MAP cascade. Overall, altered PI3K/AKT signaling was found in half of the patients, followed by alterations in NOTCH signaling enriched in 20% of patients. To explore the effect of treatment on evolutionary states we investigated clonal compositions and enriched pathways in the after-treatment samples. Interestingly, 62% of the neoadjuvant chemotherapy treated (three cycles of platinum & paclitaxel) samples remained in the same evolutionary state as compared to the treatment-naïve samples from the same patients, indicating that the neoadjuvant therapy does not significantly alter tumor composition. Analysis of relapse samples revealed that signal transduction via PI3K/AKT and NOTCH was enriched after the full course of treatment (including platinum-taxane chemotherapy, surgery, possible maintenance therapy with PARP inhibitors or angiogenesis inhibitors), which testifies for their central role in treatment failure. Taken together, our results show that integrating clonal composition and heterogeneity at diagnosis allows allocation of HGSC tumors into three states with different prognosis. Aberrations in PI3K/AKT or NOTCH signaling, distinctive for higher evolved “maintaining” and “adaptive” states, are key pathways to the development of chemoresistant clones. As the herein identified pathways can be targeted by several clinically approved drugs, our results provide a means to identify effective, combinatorial personalized treatments for HGSC patients at the relapse setting. Citation Format: Alexandra Lahtinen, Kari Lavikka, Yilin Li, Sanaz Jamalzadeh, Anni Virtanen, Rainer Lehtonen, Olli Carpén, Sakari Hietanen, Kaisa Huhtinen, Antti Häkkinen, Johanna Hynninen, Jaana Oikkonen, Sampsa Hautaniemi. Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on the Evolutionary Dynamics in Carcinogenesis and Response to Therapy; 2022 Mar 14-17. Philadelphia (PA): AACR; Cancer Res 2022;82(10 Suppl):Abstract nr PR003.

Abstract 1617: Tumor evolution during therapy in ovarian cancer

Abstract PR-001: Stable subclones and acquired genomic events present after treatment of HGSC

Abstract PR003: Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer

Abstract 5344: Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer

Abstract 1513: A multi-sample study reveals the evolution and heterogeneity in high-grade serous ovarian cancer

Abstract 3790: A study of evolutionary dynamics induced by carboplatin, olaparib and paclitaxel in high-grade serous ovarian cancer cell line models

Abstract P3-06-01: Clonal Evolution and Heterogeneity in Breast Tumors Treated with Neoadjuvant HER2-targeted Therapy

Abstract A057: Inter-tumor heterogeneity revealed by multi-site whole genome sequencing of high grade serous ovarian cancer

Abstract PR015: Developing adaptive therapy to suppress the evolution of treatment resistance in high-grade serous ovarian cancer

Abstract A010: Integration of clonal composition and tumor heterogeneity reveals novel evolutionary states and intervention targets in ovarian cancer

Abstract B083: Single-cell and spatial transcriptomic characterization of treatment resistance and immune dynamics in high-grade serous ovarian cancer

Abstract 7353: Exploring intrapatient heterogeneity in metastatic breast cancer: Insights into tumor evolution from a warm procurement trial

Evolutionary States and Trajectories Characterized by Distinct Pathways Stratify Patients with Ovarian High Grade Serous Carcinoma

Abstract PR011: Comprehensive longitudinal tracking of lung cancer evolutionary clonal dynamics during therapy using circulating tumour DNA

Abstract 4336: Homologous recombination repair deficiency, and not recurrence, determines mutational burden and clonal dynamics in high grade serous ovarian cancer

Abstract 4940: Unraveling ctDNA features in high-grade serous ovarian carcinoma and insights from genomic and transcriptomic integration

Abstract 6943: Evolutionary dynamics under chemotherapy in small cell lung cancer: Insights from patient-derived xenotransplant models

Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA

Abstract 1516: Deep profiling of T-cell repertoire and tumor heterogeneity in chronic lymphocytic leukemia patients following allogeneic T-cell therapy

Abstract PR-004: The evolution of ovarian high grade serous carcinoma from STIC lesions

Abstract 2135: Multi-omics Characterization of Chemo-Refractory HGSC Patients